Back to results
US 2010/0251425 A9Published application
Expression of human interferon in transgenic chloroplasts
AssigneeUniversity of Central Florida
InventorHenry Daniell
Life of this patent
Estimating the term…
Loading patent…
Loading patent…
AssigneeUniversity of Central Florida
InventorHenry Daniell
Estimating the term…
A plastid transformation vector for a stably transforming a plastid genome is provided. The vector includes, as operably-linked components, a first flanking sequence, a DNA sequence coding for a therapeutic human IFN, which is capable of expression in the plastid and a second flanking sequence. The invention also provides isolated and purified IFN, wherein the IFN is configured in a monomeric or multimeric form and is a structural equivalent to orally administered human IFN. Also provided are methods for variable-expressing biopharmaceutical proteins in plants suitable for mammal consumption. The method includes integrating a plastid transformation vector into a plastid genome of a plant cell; growing the plant cell to express a biopharmaceutical protein, such as therapeutic human interferon IFN. Also disclosed are plants transformed with the aforementioned vectors, and the progeny thereof. Also, disclosed is the IFN, which is IFNα2b.
A plastid transformation vector for stably transforming a plastid, comprising, as operably-linked components, a first flanking sequence, a DNA sequence coding for a therapeutic human interferon (1N), which is capable of expression in a plastid, and a second flanking sequence.
An isolated and purified IFN, competent to produce and immunogenic response in a mammal.
An orally administerable therapeutic human interferon IFN, suitable for oral administration to a mammal.
A method of producing a biopharmaceutical protein of interest in a low-nicotine tobacco plant comprising:
A plastid transformation vector for a stably transforming a plastid genome, comprising, as operably-linked components, a first flanking sequence, a DNA sequence coding for a therapeutic human interferon IFN or a substantially homologous DNA sequence of therapeutic human interferon IFN, wherein the therapeutic human interferon IFN is operably linked to a polyhistidine purification tag and a thrombin cleavage site, and a second flanking sequence.
Dependencies are inferred from the claim text.